Notice of Closed Meeting, 69023-69024 [2022-25062]

Download as PDF Federal Register / Vol. 87, No. 221 / Thursday, November 17, 2022 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC–2022–0014] Record of Decision for the Final Supplemental Environmental Impact Statement for the Roybal Campus 2025 Master Plan Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: General notice. AGENCY: The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), announces the Record of Decision (ROD) for the Final Supplemental Environmental Impact Statement (SEIS) for CDC’s Roybal Campus in Atlanta, Georgia. DATES: The ROD was signed on November 14, 2022. FOR FURTHER INFORMATION CONTACT: Thayra Riley, NEPA Coordinator, Office of Safety, Security, and Asset Management, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H20–4, Atlanta, Georgia 30329. Email: cdc-roybalgaseis@cdc.gov. Telephone: 770–488– 8170. SUMMARY: SUPPLEMENTARY INFORMATION: In accordance with the National Environmental Policy Act of 1969 (NEPA), as implemented by the Council on Environmental Quality regulations (40 CFR 1507.3) and HHS General Administration Manual Part 30 environmental procedures, CDC is issuing a ROD based on the Final SEIS that analyzed the effects of additional proposed components that were not analyzed in the 2014 Final Environmental Impact Statement. lotter on DSK11XQN23PROD with NOTICES1 Public Participation On January 28, 2022, CDC published a Notice of Intent to prepare a SEIS in the Federal Register (87 FR 4603). CDC announced a Notice of Availability (NOA) of the Draft SEIS on July 8, 2022 (87 FR 40844) and the public comment period ended August 22, 2022. During the public comment period, a virtual public meeting was held on July 27, 2022. Two participants attended the meeting. CDC received five public comments. CDC made minor revisions to the Final SEIS based on these comments. The comments and CDC’s responses are included in Appendix A of the Final SEIS found in the Supporting Materials tab of the docket. VerDate Sep<11>2014 17:26 Nov 16, 2022 Jkt 259001 69023 On October 14, 2022, CDC published the NOA for the Final SEIS in the Federal Register (87 FR 62413). DEPARTMENT OF HEALTH AND HUMAN SERVICES Decision Centers for Disease Control and Prevention Based on the Final SEIS, CDC has decided to implement Alternative 1 (Preferred Alternative) as the selected alternative. This Alternative includes the construction and operation of a new Hazardous/Medical/Infectious Waste Incinerator in a new laboratory building, the operation of two proposed emergency standby power diesel generators to support that laboratory, and annual testing of the generators. According to the analysis, no potential significant impacts were identified for the selected alternative. CDC’s decision is based on an analysis of the potential impacts of the alternatives considered in the SEIS weighed against CDC’s continuing need to fulfill its unique and critical public health mission and its ability to mitigate in whole or in part the adverse impacts. CDC also considered the input from the public and agencies, such as the U.S. Fish and Wildlife Service, Georgia Department of Natural Resources, Georgia Environmental Protection Division (EPD), and Georgia Historic Preservation Division. Compliance Requirements The ROD includes these additional compliance requirements: CDC will obtain an updated Title V Operating Air Permit from Georgia EPD and treat and dispose of waste in accordance with Georgia EPD, Biomedical Waste (Rule 391–3–4–.15). Availability of the ROD: The ROD is available in the Supplemental Materials tab of the docket found on the Federal eRulemaking Portal: https:// www.regulations.gov, identified by Docket No. CDC–2022–0014. The public is being notified of the ROD through this Federal Register publication and the NOA has been provided to interested parties via electronic mail. Dated: November 14, 2022. Angela K. Oliver, Executive Secretary, Centers for Disease Control and Prevention. [FR Doc. 2022–25047 Filed 11–16–22; 8:45 am] BILLING CODE 4163–18–P PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)— RFA–IP–23–006, Developing a Public Health Tool to Predict the Virality of Vaccine Misinformation Narratives; and RFA–IP–23–007, Collaborative Surveys to Provide Inputs into Vaccine-Related Economic Evaluations. Date: March 7, 2023. Time: 10:00 a.m.–5:00 p.m., EST. Place: Teleconference, Centers for Disease Control and Prevention, Room 1080, 8 Corporate Boulevard, Atlanta, Georgia 30329. Agenda: To review and evaluate grant applications. FOR FURTHER INFORMATION CONTACT: Gregory Anderson, M.S., M.P.H., Scientific Review Officer, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, 1600 Clifton Road NE, Mailstop US8–1, Atlanta, Georgia 30329–4027; Telephone: (404) 718–8833; Email: GAnderson@cdc.gov. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and E:\FR\FM\17NON1.SGM 17NON1 69024 Federal Register / Vol. 87, No. 221 / Thursday, November 17, 2022 / Notices Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2022–25062 Filed 11–16–22; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day—23–1273] lotter on DSK11XQN23PROD with NOTICES1 Agency Forms Undergoing Paperwork Reduction Act Review In accordance with the Paperwork Reduction Act of 1995, the Centers for Disease Control and Prevention (CDC) has submitted the information collection request titled ‘‘Pregnancy Risk Assessment Monitoring System (PRAMS)’’ to the Office of Management and Budget (OMB) for review and approval. CDC previously published a a ‘‘Proposed Data Collection Submitted for Public Comment and Recommendations’’ notice on July 5, 2022, to obtain comments from the public and affected agencies. CDC received two comments related to the previous notice. This notice serves to allow an additional 30 days for public and affected agency comments. CDC will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and clarity of the information to be collected; (d) Minimize the burden of the collection of information on those who are to respond, including, through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and (e) Assess information collection costs. VerDate Sep<11>2014 17:26 Nov 16, 2022 Jkt 259001 To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570. Comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/ do/PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 395–5806. Provide written comments within 30 days of notice publication. Proposed Project Pregnancy Risk Assessment Monitoring System (PRAMS) (OMB Control No. 0920–1273, Exp. 11/30/ 2022)—Revision—National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC). Background and Brief Description The Pregnancy Risk Assessment Monitoring System (PRAMS) is a surveillance project of the Centers for Disease Control and Prevention (CDC) and jurisdiction (e.g., state, city, territory) health departments. Developed in 1987, PRAMS collects jurisdiction-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. PRAMS provides data on the experiences of women with a recent live or stillbirth not available from other sources. These data can be used to identify groups of women and infants at high risk for health problems, to monitor changes in health status, and to measure progress towards goals in improving the health of mothers and infants. PRAMS data are used by researchers to investigate emerging issues in the field of reproductive health and by federal, state and local governments to plan and review programs and policies aimed at reducing health problems among mothers and babies. PRAMS is a jurisdiction-customized survey conducted in 50 sites and covers 81% of all live births in the United States. Because PRAMS uses standardized data collection methods, it allows data to be compared among sites. Jurisdictions can implement the survey on an ongoing basis or as a point-in-time survey. In participating jurisdictions, a PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 sample of women who have recently given birth to a live born or stillborn infant is selected from birth certificates or fetal death files. The sample is stratified based on the site’s population of interest to ensure high-risk populations are adequately represented in the data. The PRAMS survey instrument for live births is based on a core set of questions common across all jurisdictions that remain the same throughout each phase of data collection. In addition, CDC provides optional standardized modules (pregrouped questions on a select topic) that a jurisdiction may use to customize survey content at the beginning of each phase of data collection. Topics for both the core and standard modules include health conditions (which includes chronic conditions such as diabetes, hypertension, mental health, oral health, cancer, as well as pregnancyinduced health conditions and family history of select conditions); health behaviors (including tobacco and alcohol use, substance use [licit and illicit], injury prevention and safety, nutrition, and physical activity); health care services (such as preconception care, prenatal care, postpartum care, contraceptive care, vaccinations, access to care and insurance coverage, receipt of recommended services and provider counseling received); infant health and development; infant care practices (such as breastfeeding, safe sleep practices); social services received (such as WIC or home visiting); the social context of childbearing (such as intimate partner violence, social support, adverse childhood experiences, stressful life experiences and racism); attitudes and feeling about the pregnancy including pregnancy intentions. PRAMS Phase 8 includes births that occur/will have occurred during calendar years 2016–2022. Phase 8 data collection will cease for December 2022 births by the end of June 2023. For calendar year 2023 births, PRAMS will transition to Phase 9 (data collection for January 2022 births to begin in April 2023). The Phase 9 survey will include the same question topics and most of the same questions for core and standard modules listed above from Phase 8. The content on some topics will be expanded, for example, questions related to social determinants of health have been broadened with new questions such as those on experiences of racism and food, housing, and transportation insecurity. For Phase 9, some Phase 8 questions have been modified (e.g., by reducing the number of response choices). Additionally, some questions from the Phase 8 core E:\FR\FM\17NON1.SGM 17NON1

Agencies

[Federal Register Volume 87, Number 221 (Thursday, November 17, 2022)]
[Notices]
[Pages 69023-69024]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-25062]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended, and the Determination of the Director, Strategic 
Business Initiatives Unit, Office of the Chief Operating Officer, CDC, 
pursuant to Public Law 92-463. The grant applications and the 
discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.
    Name of Committee: Disease, Disability, and Injury Prevention and 
Control Special Emphasis Panel (SEP)--RFA-IP-23-006, Developing a 
Public Health Tool to Predict the Virality of Vaccine Misinformation 
Narratives; and RFA-IP-23-007, Collaborative Surveys to Provide Inputs 
into Vaccine-Related Economic Evaluations.
    Date: March 7, 2023.
    Time: 10:00 a.m.-5:00 p.m., EST.
    Place: Teleconference, Centers for Disease Control and Prevention, 
Room 1080, 8 Corporate Boulevard, Atlanta, Georgia 30329.
    Agenda: To review and evaluate grant applications.

FOR FURTHER INFORMATION CONTACT: Gregory Anderson, M.S., M.P.H., 
Scientific Review Officer, National Center for HIV, Viral Hepatitis, 
STD, and TB Prevention, CDC, 1600 Clifton Road NE, Mailstop US8-1, 
Atlanta, Georgia 30329-4027; Telephone: (404) 718-8833; Email: 
[email protected].
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and

[[Page 69024]]

Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-25062 Filed 11-16-22; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.